RxDoctor Payments Data

Tingting Wong, MD

Infectious Disease · Brooklyn, NYNPI 1174862866

Payments from drug & device makers

$1,137in general payments, 2019–2025

Across 48 payments — averaging $23.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • Janssen Products, LP$72
  • Gilead$23

What the payments were for

  • Food & beverage$1,137100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson46$1,042
Janssen Products, LP1$72
Gilead1$23

How this compares

$1,137 in reported general payments places this provider in the 65th percentile of 799 infectious disease providers in New York.

See all infectious disease providers in New York

Medicare billing

Part B allowed, 2024
$274,014
Medicare patients
428
Services billed
2,562

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala88$375,865
OdefseyEmtricitab/Rilpiviri/Tenof Ala84$305,267
JulucaDolutegravir/Rilpivirine74$289,399
GenvoyaElviteg/Cob/Emtri/Tenof Alafen46$181,609
PrezcobixDarunavir/Cobicistat72$174,462
TivicayDolutegravir Sodium69$152,189
DescovyEmtricitabine/Tenofov Alafenam47$139,033
CabenuvaCabotegravir/Rilpivirine13$76,599
TriumeqAbacavir/Dolutegravir/Lamivudi16$55,453
PrezistaDarunavir16$33,649
IsentressRaltegravir Potassium12$22,076
EdurantRilpivirine Hcl13$21,258
Nevirapine ErNevirapine32$12,989
VascepaIcosapent Ethyl41$11,611
Emtricitabine-Tenofovir DisopEmtricitabine/Tenofovir (Tdf)18$6,960

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$23$696,507181 claims
Johnson & JohnsonPrezcobix$1,042$174,46272 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 799 infectious disease providers in New York.

Other infectious disease in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →